Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?
Alsyouf M, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S; Blue Light Cystoscopy with Cysview Registry Group. Alsyouf M, et al. Among authors: konety b. Urol Oncol. 2023 Feb;41(2):109.e9-109.e14. doi: 10.1016/j.urolonc.2022.10.026. Epub 2022 Nov 24. Urol Oncol. 2023. PMID: 36435710
A multi-institutional study of 1,111 men with 4K score, multiparametric magnetic resonance imaging, and prostate biopsy.
Thomas J, Atluri S, Zucker I, Reis I, Kwon D, Kim E, Tewari A, Patel V, Wagaskar V, Konety B, Kasraeian A, Czarniecki S, Thoreson G, Soodana-Prakash N, Ritch C, Nahar B, Gonzalgo M, Kava B, Parekh D, Punnen S. Thomas J, et al. Among authors: konety b. Urol Oncol. 2023 Oct;41(10):430.e9-430.e16. doi: 10.1016/j.urolonc.2023.07.001. Epub 2023 Aug 4. Urol Oncol. 2023. PMID: 37544833
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.
Ladi-Seyedian SS, Ghoreifi A, Konety B, Pohar K, Holzbeierlein JM, Taylor J, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light Cystoscopy With Cysview Registry Group. Ladi-Seyedian SS, et al. Among authors: konety b. Cancers (Basel). 2024 Mar 24;16(7):1268. doi: 10.3390/cancers16071268. Cancers (Basel). 2024. PMID: 38610946 Free PMC article.
Identifying the best candidate for focal therapy: a comprehensive review.
Ghoreifi A, Gomella L, Hu JC, Konety B, Lunelli L, Rastinehad AR, Salomon G, Taneja S, Tourinho-Barbosa R, Lebastchi AH. Ghoreifi A, et al. Among authors: konety b. Prostate Cancer Prostatic Dis. 2024 Oct 23. doi: 10.1038/s41391-024-00907-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39443815 Review.
Clinical use of nadofaragene firadenovec-vncg.
Konety BR, Shore ND, Sant GR. Konety BR, et al. Ther Adv Urol. 2024 Sep 17;16:17562872241280005. doi: 10.1177/17562872241280005. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 39315392 Free PMC article. Review.
Does sexual rehabilitation work for gay and bisexual prostate cancer patients? Acceptability, feasibility, and efficacy results from the Restore-2 randomized controlled trial.
Rosser BRS, Kohli N, Bates AJ, Talley KMC, Wright MM, Polter EJ, Wheldon CW, Haggart R, Dickstein DR, Ross MW, Zhang Z, West W, Konety BR. Rosser BRS, et al. Among authors: konety br. J Cancer Surviv. 2024 Sep 12. doi: 10.1007/s11764-024-01672-6. Online ahead of print. J Cancer Surviv. 2024. PMID: 39266938
393 results